Last reviewed · How we verify
NCT06793215: Krascendo 2
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 trial testing Divarasib in Non-Small Cell Lung Cancer in 600 participants. Currently enrolling.
30 November 2028
Quick facts
| Lead sponsor | Hoffmann-La Roche |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 600 |
| Start date | 24 October 2025 |
| Primary completion | 30 November 2028 |
| Estimated completion | 31 October 2030 |
| Sites | 217 locations across Hong Kong, Italy, Japan, Taiwan, Ireland, Poland, South Korea, Denmark |
Drugs / interventions tested
- Divarasib
- Pembrolizumab (pembrolizumab) — full drug profile →
- Pemetrexed — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
Conditions studied
- Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
- KRAS G12C Lung Cancer — all drugs for KRAS G12C Lung Cancer →
Sponsor
Hoffmann-La Roche — full company profile →
Who can join
18 and older, any sex, with Non-Small Cell Lung Cancer or KRAS G12C Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Response and Resistance to RAS Inhibition in Cancer.
Ebright RY, Dilly J, Shaw AT, Aguirre AJ. · · 2025 · cited 16× · PMID 40293709 · DOI 10.1158/2159-8290.cd-25-0349 -
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C.
Endres NF, Do S, Mroue R, Terrett JA, et al · · 2026 · cited 1× · PMID 41766690 · DOI 10.1021/acs.jmedchem.5c02272 -
Global advances and future directions in lung cancer care: expert consensus and strategic priorities.
Meyer ML, Peters S, Jänne PA, Mok TS, et al · · 2026 · cited 1× · PMID 41579430 · DOI 10.1016/j.esmoop.2025.106034 -
Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies.
Wang W, Alley A, Sun N, Tadesse M, et al · · 2025 · PMID 41170373 · DOI 10.3389/fphar.2025.1663766
Verify or expand the search:
- PubMed search for NCT06793215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Divarasib
Trials testing the same drug.
- NCT06835465 — A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants · Phase 1 · completed
- NCT06734208 — A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Fun · Phase 1 · completed
- NCT06690138 — A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants · Phase 1 · completed
- NCT06677957 — A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein · Phase 1 · completed
- NCT06497556 — A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Tr · Phase 3 · active not recruiting
Other recruiting trials for Non-Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
- NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
- NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
- NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
- NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
- NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06793215 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06793215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing